Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Maintenance therapy with CC-486 for acute myeloid leukaemia

Prof Andrew Wei - Monash University, Melbourne, Australia

Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Daratumuab, carfilzomib and dexamethasone increases survival in patients with...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome...

Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients...

Prof Andrew Wei - Monash University, Melbourne, Australia

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Blinatumomab demonstrates superior efficacy compared to chemotherapy in...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Multiple myeloma highlights from ASH 2019

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed...

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

$MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Glasdegib in combination with azacitidine in patients with untreated higher...

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )

Addressing the treatment gap for patients with relapsed/refractory primary...

Prof Evangelos Terpos and Prof Efstathios Kastritis

$Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )$

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Challenges and importance of long-term treatment for newly diagnosed multiple...

Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin

Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell...

Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA

Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )

More from ecancer